Juvenescence is an anti-aging company looking to develop preventative therapeutics for aging, which they believe will slow down the onset of chronic diseases associated with aging. The name of the company refers to the state of being youthful or of growing young.
Feel welcome to share your own thoughts on this company in the comment section below as well. I will be happy to discuss and learn more about how you see their potential in this field.
The solution
There is a lot going on at Juvenescence in terms of solutions so I will focus on what I find the most interesting from an anti-aging perspective, which is their pipeline. In their pipeline they have many different programs running in parallel. It does makes you wonder if they are just throwing everything at the wall to see what sticks, but I hope there is more focus behind it than what it appears like – and resources to see this potentially long list of clinical trials through.
According to Juvenescence the common denominator for the pipeline programs is that these potential therapeutics target the underlying causes of diseases associated with aging.
You can view their official pipeline in the below image from their website:
The lead candidate is the PAI-1 inhibitor indicated for fibrotic disease with a novel mechanism of action, which should be running their phase 1 clinical trials as I am writing this. It appears that in May 2022 Juvenescence invested $9M in a partnership with MDI Therapeutics in order to move forward with the phase 1 clinical trial. However, I have been unable to find much more information about the progress here.
Additionally, the GDF15 mAb, CD38 inhibitor, and Ketone Rx programs are all slated to move from pre-clinical to phase 1 clinical trials throughout the year of 2024. This is of course assuming they achieve promising results from the preclinical studies.
It is a truly impressive pace that Juvenescence are moving with if they are able to keep up with their official pipeline. It will be very interesting to follow the progress and outcome of their trials. I for one am curious to know more about the potential for the high ranking candidates, but they do seem to be playing their cards close to their chest still.
The company
Juvenescence was founded in 2016 by Declan Doogan, Jim, Mellon, and Greg Bailey.
The company has an ongoing series B-1 funding round and recently closed the first tranche with a $76M investment led by Abu Dhabi’s M42. It is a serious capital injection for Juvenescence to help accelerate the array of programs in their pipeline. This investment comes alongside a strategic partnership that aims to establish a leading drug development hub in Abu Dhabi.
Juvenescence is hoping to complete the second tranche of this funding round by Q3 of 2025.
The previous round of funding was back in April of 2020. This was a series C round raising an undisclosed amount. This funding series was conducted ahead of an alleged IPO of the company. Usually this is done to accommodate strategic investors. However, at this point, Juvenescence has not initiated an IPO and is not listed on any stock exchange. It is a bit curious that information is sparce on this topic with nothing conclusive to be found.
If you want to learn more about Juvenescence you can view their official website through this link.
Read about more anti-aging companies on this website through this link.
